Logo image of ACLX

ARCELLX INC (ACLX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACLX - US03940C1009 - Common Stock

65.5 USD
-0.5 (-0.76%)
Last: 12/26/2025, 12:43:19 PM
Fundamental Rating

3

ACLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACLX as it has an excellent financial health rating, but there are worries on the profitability. ACLX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACLX has reported negative net income.
ACLX had a negative operating cash flow in the past year.
ACLX had negative earnings in each of the past 5 years.
In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of ACLX (-33.22%) is better than 64.34% of its industry peers.
Looking at the Return On Equity, with a value of -49.44%, ACLX is in the better half of the industry, outperforming 65.66% of the companies in the same industry.
Industry RankSector Rank
ROA -33.22%
ROE -49.44%
ROIC N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ACLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACLX has more shares outstanding
ACLX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ACLX has an improved debt to assets ratio.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 8.70 indicates that ACLX is not in any danger for bankruptcy at the moment.
ACLX has a Altman-Z score of 8.70. This is in the better half of the industry: ACLX outperforms 79.81% of its industry peers.
ACLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.7
ROIC/WACCN/A
WACC8.77%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ACLX has a Current Ratio of 3.99. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
ACLX has a Current ratio (3.99) which is in line with its industry peers.
ACLX has a Quick Ratio of 3.99. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
ACLX has a Quick ratio (3.99) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.99
Quick Ratio 3.99
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ACLX have decreased strongly by -453.52% in the last year.
ACLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.96%.
EPS 1Y (TTM)-453.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.25%
Revenue 1Y (TTM)-76.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.99%

3.2 Future

The Earnings Per Share is expected to grow by 27.40% on average over the next years. This is a very strong growth
ACLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.78% yearly.
EPS Next Y-106.44%
EPS Next 2Y-31.87%
EPS Next 3Y-10.94%
EPS Next 5Y27.4%
Revenue Next Year-72.5%
Revenue Next 2Y5.2%
Revenue Next 3Y24.03%
Revenue Next 5Y42.78%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

ACLX's earnings are expected to decrease with -10.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.87%
EPS Next 3Y-10.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACLX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ARCELLX INC

NASDAQ:ACLX (12/26/2025, 12:43:19 PM)

65.5

-0.5 (-0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-17 2026-03-17/amc
Inst Owners94.1%
Inst Owner Change3.04%
Ins Owners1.19%
Ins Owner Change-2.6%
Market Cap3.79B
Revenue(TTM)35.90M
Net Income(TTM)-217.90M
Analysts84.8
Price Target113.97 (74%)
Short Float %13.47%
Short Ratio7.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.93%
Min EPS beat(2)8.44%
Max EPS beat(2)9.43%
EPS beat(4)2
Avg EPS beat(4)-20.07%
Min EPS beat(4)-51.89%
Max EPS beat(4)9.43%
EPS beat(8)5
Avg EPS beat(8)19.46%
EPS beat(12)5
Avg EPS beat(12)-13.28%
EPS beat(16)6
Avg EPS beat(16)-113.7%
Revenue beat(2)0
Avg Revenue beat(2)-48.99%
Min Revenue beat(2)-52.37%
Max Revenue beat(2)-45.6%
Revenue beat(4)0
Avg Revenue beat(4)-50.17%
Min Revenue beat(4)-60.26%
Max Revenue beat(4)-42.43%
Revenue beat(8)3
Avg Revenue beat(8)22.26%
Revenue beat(12)3
Avg Revenue beat(12)-6.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.97%
PT rev (3m)-1.18%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-4.61%
EPS NY rev (1m)-1.34%
EPS NY rev (3m)0.01%
Revenue NQ rev (1m)-14.15%
Revenue NQ rev (3m)-23.37%
Revenue NY rev (1m)-24.1%
Revenue NY rev (3m)-22.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 105.5
P/FCF N/A
P/OCF N/A
P/B 8.59
P/tB 8.59
EV/EBITDA N/A
EPS(TTM)-3.93
EYN/A
EPS(NY)-3.48
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.43
OCFYN/A
SpS0.62
BVpS7.62
TBVpS7.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.22%
ROE -49.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.86%
Cap/Sales 8.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.99
Quick Ratio 3.99
Altman-Z 8.7
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)494.02%
Cap/Depr(5y)435.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-453.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.25%
EPS Next Y-106.44%
EPS Next 2Y-31.87%
EPS Next 3Y-10.94%
EPS Next 5Y27.4%
Revenue 1Y (TTM)-76.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.99%
Revenue Next Year-72.5%
Revenue Next 2Y5.2%
Revenue Next 3Y24.03%
Revenue Next 5Y42.78%
EBIT growth 1Y-249.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-118.63%
EBIT Next 3Y0.05%
EBIT Next 5Y27.9%
FCF growth 1Y-292.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-262.65%
OCF growth 3YN/A
OCF growth 5YN/A

ARCELLX INC / ACLX FAQ

What is the fundamental rating for ACLX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACLX.


Can you provide the valuation status for ARCELLX INC?

ChartMill assigns a valuation rating of 0 / 10 to ARCELLX INC (ACLX). This can be considered as Overvalued.


What is the profitability of ACLX stock?

ARCELLX INC (ACLX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ARCELLX INC?

The Earnings per Share (EPS) of ARCELLX INC (ACLX) is expected to decline by -106.44% in the next year.